Reuters
24 Jun 2026, 11:36 UTC · 2h ago
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
24 Jun 2026, 11:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
ALZpath has entered into a global licensing agreement with Abbott Laboratories for blood-based Alzheimer's testing. — Partnership with a healthcare giant like Abbott provides significant commercial validation and a distribution pathway for ALZpath's technology.
+0.60Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] Abbott Laboratories signed a global licensing agreement with ALZpath for Alzheimer's blood-based testing.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
